Publication: An open label trial of pergolide in Thai patients with Parkinson's disease
1
Issued Date
1996-08-20
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-0030055669
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.79, No.4 (1996), 205-209
Suggested Citation
N. Poungvarin, N. Prayoonwiwat, V. Devahasatin, A. Viriyavejakul An open label trial of pergolide in Thai patients with Parkinson's disease. Journal of the Medical Association of Thailand. Vol.79, No.4 (1996), 205-209. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/17720
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
An open label trial of pergolide in Thai patients with Parkinson's disease
Other Contributor(s)
Abstract
Fifteen Thai patients with Parkinson's disease (7 females, 8 males) were enrolled in an open label trial of pergolide (a new dopamine agonist) to evaluate its safety and efficacy. Inpatients and out patients from Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand from 1992 to 1994 were included in the study with a total duration of 18 weeks. Both de novo patients and patients who were being treated with levodopa without dopamine agonist and were obtaining a less than optimal response at both visit 1 and visit 2 were all enrolled in this study. At entry into the study, 3 patients had Hoehn and Yahr stage I, 7 patients at stage II, 3 patients at stage III, and 2 patients at stage IV. Pergolide dosage was gradually built up until an optimal dosage was achieved. The average dose of pergolide during the study was 0.94 mg/day (range 0.075 to 8 mg/day). All patients completed the study and no patients dropped out. Two patients (13.33 per cent) experienced nausea (on 0.4 mg/ day and 0.075 mg/day), two patients (13.33 per cent) experienced sleepiness (0.50 mg/day and 0.075 mg/day) and one patient (6.67 per cent) unsteadiness on walking (0.50 mg/day). There was one patient who required pergolide up to 8 mg/day which is higher than the recommended dosage (5 mg/day) but this patient experienced no adverse effects and his disabled dyskinesic was abolished. Our study demonstrated the good toleration and efficacy of pergolide treatment for Thai patients with Parkinson's disease. This new dopamine agonist stimulates both D1 and D2 receptors in comparison to other dopamine agonists (bromocriptine and lisuride) which stimulate only D2 receptors.